相关实验视频

Updated: May 2, 2026

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

与容易肥胖的老鼠相比,抗肥胖的老鼠的身体表现改善:不同饮食和代谢分析的影响

Daniel Sesana da Silva¹, Matheus Corteletti Dos Santos¹, Lucas Furtado Domingos²

¹Postgraduate Program in Physiological Sciences, Center of Health Sciences, Federal University of Espírito Santo, Vitória, Espírito Santo, Brazil.

|July 7, 2025

概括

与易患肥胖 (OP) 的老鼠相比,抗肥胖 (OR) 的老鼠表现出优越的体力表现和有氧能力. 这些发现突出了OR大鼠的适应机制,这些机制可以增强能量代谢和耐力,即使是在高脂肪饮食条件下.

科学领域:

代谢生理学代谢生理学
肥胖病理生理学肥胖病理生理学
饮食诱导肥胖的动物模型

背景情况:

在饮食诱导肥胖 (DIO) 的动物模型中存在易患肥胖 (OP) 和耐肥胖 (OR) 的表型.
或表型表现出较低的体重增加和更高的体力活动,表明更有效的能量代谢.
了解这些差异对于阐明肥胖病理生理学至关重要.

研究的目的:

为了评估OP和OR大鼠之间的代谢适应和身体性能差异.
研究标准饮食 (SD) 和高脂肪饮食 (HFD) 对这些表型的影响.
确定有助于抗肥胖的潜在机制.

主要方法:

威斯塔大鼠接受了23周的SD或HFD协议,并被分为OP或OR.
评估了营养,代谢和脂肪的参数.
间接热量计测量了基础代谢,跑步机测试确定了身体表现和最大氧气消耗 (VO2max).

主要成果:

尽管OR老鼠的热量摄入量相似,但它们的体重比OP老鼠要低.
HFD-OP老鼠的体重增加明显高于HFD-OR老鼠 (30.5%).
OR老鼠表现出更高的VO2max和耐力,在黑暗周期中增加能量消耗,以及不同的荷尔蒙特征 (瘦素,葡萄糖).

结论:

与容易肥胖的老鼠相比,耐肥胖的老鼠表现出更好的体力表现和有氧能力.
这些适应性表明OR大鼠具有高效的能量代谢和耐力机制,即使面临高脂肪饮食的挑战.
这项研究提供了对抗肥胖的生理基础的见解.

更多相关视频

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

相关概念视频

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...